Thursday, October 11, 2007

Revimmune News -
Dr. Howard Weiner August 5, 2007:
Radio Interview for Revimmune for MS

http://www.accentia.net/media/revimmune_ms4.html

Accentia BioPharmaceuticals | Home


http://www.accentia.net/

Accentia applies for IND for Revimmune
Pharmaceutical Business Review - USA
By Staff Writer The Revimmune multiple sclerosis (MS) study will enroll subjects in a one-year study comparing baseline disability to disability at month 12 ...
See all stories on this topic

MS vaccine trials hold promise
London Free Press - Canada
The vaccine about which she is particularly excited is BHT-3009, designed to stop an individual's immune system from attacking the myelin sheaths that ...
See all stories on this topic

Biogen, PDL BioPharma hail MS drug data
CNNMoney.com - USA
Specifically, the Phase 2 data showed daclizumab significantly reduced multiple sclerosis lesions in patients receiving interferon beta therapy. ...
See all stories on this topic

Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
The San Francisco Examiner Thu, 11 Oct 2007 1:26 PM PDT
CAMBRIDGE, Mass. and BERLIN /PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer Schering Pharma AG, Germany announce that important, new clinical data will be presented this weekend from two studies regarding alemtuzumab use in patients with multiple sclerosis (MS) at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) underway in Prague .

Genes That Affect Responses Of Multiple Sclerosis Patients To Copaxone Identified
Science Daily Wed, 10 Oct 2007 9:07 PM PDT
Getting the drug dosage correct can be a tricky exercise in trial and error in a disease like multiple sclerosis. Scientists have identified two genes that affect a patient's response to the drug Copaxone, a finding which may help take the some of the guesswork out of treatment.

New genetic understanding of multiple sclerosis patients response to Copaxone
News-Medical-Net Thu, 11 Oct 2007 4:02 AM PDT
A group of Israeli scientists from the Technion - Israel Institute of Technology, the Weizmann Institute of Science, and Teva Pharmaceutical Industries have recently identified genes responsible for the positive response of many multiple sclerosis (MS) patients to the drug Copaxone.

Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta ...
The San Francisco Examiner Thu, 11 Oct 2007 2:25 PM PDT
Oct 11, 2007 9:26 AM (4 hrs ago) From Biogen Idec Inc., Distributed by Press Release

No new cases of brain infection with Biogen drug
Reuters via Yahoo! News Thu, 11 Oct 2007 12:58 PM PDT
Biogen Idec Inc and partner Elan Corp said on Thursday that as of the end of September there have been no new reported cases of a potentially deadly brain infection in patients taking their multiple sclerosis drug Tysabri.

Interferon Beta-1a Offers A Near 3-fold Improvement In Injection Tolerability Compared With The Original Formulation - ...
Medical News Today Thu, 11 Oct 2007 8:16 AM PDT
Merck Serono, a division of Merck KGaA, announced today new results of a two year (96 week) Phase IIIb study in 260 patients which has shown that the new formulation of Rebif® (interferon beta-1a) offers a near three-fold improvement in injection tolerability for patients with relapsing remitting multiple sclerosis (RRMS). [click link for full article]

Scientists ID Genes Affecting MS Patient Response To Copaxone
Medical News Today Thu, 11 Oct 2007 3:15 AM PDT
A group of Israeli scientists from the Technion Israel Institute of Technology, the Weizmann Institute of Science, and Teva Pharmaceutical Industries have recently identified genes responsible for the positive response of many multiple sclerosis (MS) patients to the drug Copaxone®. These findings may contribute to the development of personalized medicine for MS sufferers. [click link for full ...

Cognitive Impairment Due To Chronic Lyme Disease Discovered In First Placebo-Controlled Study
Medical News Today Thu, 11 Oct 2007 5:15 AM PDT
Findings from the first placebo-controlled study of chronic cognitive impairment after treated Lyme disease (also known as chronic Lyme encephalopathy) demonstrate that patients report moderate cognitive impairment, physical dysfunction comparable to patients with congestive heart failure, and fatigue comparable to patients with multiple sclerosis. [click link for full article]

Third option for stem cell storage
Calcutta Telegraph - Calcutta,India
Research into the use of these cells has shown that adult stem cells can also be used to treat autoimmune diseases like lupus, multiple sclerosis, ...
See all stories on this topic

NeoStem Announces Further Expansion in Northeastern US with ...
Business Wire (press release) - San Francisco,CA,USA
NECC will be among the world's first facilities to offer the processing and storing of adult stem cells from healthy adults for their own future therapeutic ...
See all stories on this topic

UCSF's Rowitch Selected as Howard Hughes Medical Institute Patient ...
UCSF Today - San Francisco,CA,USA
Rowitch's research also examines overlap between mechanisms in brain development and other neurological diseases, including multiple sclerosis and brain ...
See all stories on this topic

Queensland to allow embryo cloning
Gold Coast News - Molendinar,Queensland,Australia
Independent MP Dorothy Pratt, diagnosed with multiple sclerosis in 2001, voted against the Bill. "I don't want to be the one to take away anybody's hope ...
See all stories on this topic

Voters may decide on lifting stem cell ban
Detroit Free Press - United States
A group seeking to lift restrictions on embryonic stem cell research in Michigan has formed a ballot proposal committee with an eye toward a possible ...
See all stories on this topic

Hemispherx Biopharma Files New Drug Application for Ampligen as ...
CNNMoney.com - USA
Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental ...
See all stories on this topic

New TYSABRI(R) Data to Be Presented at the European Committee for ...
Ad-Hoc-News (Pressemitteilung) - Germany
... of disease-free patients with multiple sclerosis (MS) according to a post hoc analysis of the Phase III AFFIRM study to be presented on Saturday, ...
See all stories on this topic

Biogen, Elan give Tysabri safety update
CNNMoney.com - USA
In the US, there were about 10500 patients on Tysabri at the end of September and about 5500 patients in the European Union. Another 1000 patients are ...
See all stories on this topic

Phase 2 Data Show Daclizumab Significantly Reduced Multiple ...
CNNMoney.com - USA
These data will be presented tomorrow at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) in Prague, ...
See all stories on this topic

Biogen, PDL BioPharma Hail MS Drug Data
Houston Chronicle - United States
Specifically, the Phase 2 data showed daclizumab significantly reduced multiple sclerosis lesions in patients receiving interferon beta therapy. ...
See all stories on this topic

Biogen Idec Announces Multiple Sclerosis Franchise and Pipeline ...
WELT ONLINE - Germany
The two approved therapies for MS are TYSABRI®(natalizumab) and AVONEX® (Interferon beta-1a); and agents in development are BG-12 (dimethyl fumarate), ...
See all stories on this topic

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home